×
About 5,633 results

ALLMedicine™ Thyroiditis Center

Research & Reviews  1,610 results

Clinical Significance of Coexistence of Hashimoto Thyroiditis and Graves' Disease with ...
https://doi.org/10.1055/a-1562-3455
Experimental and Clinical Endocrinology & Diabetes : Offi... Machens A, Lorenz K et. al.

Sep 14th, 2021 - The association of Hashimoto thyroiditis and Graves' disease with papillary, follicular, and medullary thyroid cancer has not been comprehensively investigated until now. This comparative clinicopathological study of consecutive patients thyroidec...

Subcutaneous immunoglobulin replacement therapy in a patient with 18q deletion syndrome...
https://doi.org/10.1177/20587384211039400
International Journal of Immunopathology and Pharmacology; Hogendorf A, Szadkowska A et. al.

Sep 14th, 2021 - 18q deletion syndrome (OMIM #601808) results from a deletion of a part of a long arm of 18 chromosome and is characterized by mental retardation and congenital malformations. We present an exceptional case of a 12-year-old girl with severe phenoty...

Hypothyroid cardiomyopathy: A reversible phenocopy of hypertrophic cardiomyopathy.
https://doi.org/10.1111/echo.15183
Echocardiography (Mount Kisco, N.Y.); Cianciulli TF, Morita LA et. al.

Sep 13th, 2021 - We present the case of a 46-year-old patient with hypothyroidism secondary to Hashimoto's thyroiditis who was admitted with decompensation in the form of myxedema. A 2-D echocardiogram shows a septal asymmetric hypertrophy, with low-voltage QRS co...

Resistant type 2 amiodarone-induced thyrotoxicosis responsive to cholestyramine as an a...
https://doi.org/10.7861/clinmed.2021-0482
Clinical Medicine (London, England); Rummaan A, Maryam M et. al.

Sep 12th, 2021 - Amiodarone is a class 3 antiarrhythmic drug which may be associated with thyroid dysfunction. Amiodarone-induced thyrotoxicosis (AIT) is classified as type 1 (AIT 1; which may develop in the presence of latent autoimmune hyperthyroid condition) or...

Thyroid Function: a Target for Endocrine Disruptors, Air Pollution, and Radiofrequencies.
https://doi.org/10.2174/1871530321666210909115040
Endocrine, Metabolic & Immune Disorders Drug Targets; Di Ciaula A, Bonfrate L et. al.

Sep 11th, 2021 - Thyroid diseases are progressively increasing, mainly in terms of congenital hypothyroidism, thyroiditis, and childhood thyrotoxicosis. A rapid increase in the incidence of thyroid cancer in children and adolescents has also been observed in the l...

see more →

Guidelines  1 results

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice r...
https://doi.org/10.1007/s00520-020-05709-1
Supportive Care in Cancer : Official Journal of the Multi... Cooksley T, Girotra M et. al.

Aug 29th, 2020 - Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment, transforming outcomes in melanoma and showing benefit in a range of malignancies. Immune-mediated toxicities, stemming from increased activity within the T ...

see more →

Drugs  525 results see all →

Clinicaltrials.gov  1 results

The Association of Costimulatory Molecules and PPAR-polymorphisms With Autoimmune Thyroid Disease in Taiwan
https://clinicaltrials.gov/ct2/show/NCT01260532

Dec 15th, 2010 - Autoimmune thyroid disease is the most common organ-specific autoimmune disease. AITD include Graves' disease and Hashimoto's thyroiditis. Although the pathogenesis of AITD remains unclear, it is generally thought that the mechanisms of the diseas...

see more →

News  113 results

COVID-19 Can Cause Atypical Thyroid Inflammation
https://www.medscape.com/viewarticle/947824

Mar 21st, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Individuals who experience inflammation of the thyroid gland during acute COVID-19 illness may still have subacute thyroiditis months later even i...

Frontline Pembrolizumab Improves PFS2, HRQoL in MSI-H/dMMR mCRC
https://www.onclive.com/view/frontline-pembrolizumab-improves-pfs2-hrqol-in-patients-with-msi-h-dmmr-mcrc

Jan 16th, 2021 - Frontline pembrolizumab (Keytruda) monotherapy significantly improved the time from treatment randomization to progression on the next line of therapy or any cause death, compared to chemotherapy with or without bevacizumab (Avastin) or cetuximab ...

Advances in Immunotherapy in Metastatic Non–Small Cell Lung Cancer
https://www.onclive.com/view/advances-in-immunotherapy-in-metastatic-non-small-cell-lung-cance

Jan 11th, 2021 - Non-small cell lung cancer (NSCLC) is the most common histologic subtype of the disease, accounting for approximately 85% of cases. The recognition of targetable gene alterations and immune response has resulted in rapid changes to the therapeutic...

'Thyroid Diet': What's the Evidence?
https://www.medscape.com/viewarticle/943151

Dec 31st, 2020 - A new year is upon us, and despite the challenges we've had to face over the past several months, there appears to be light at the end of the tunnel. Now more than ever, people are looking for ways to optimize their health, and those with thyroid ...

Dr. Brahmer on the PD-1 Immunotherapy BMS-936558
https://www.onclive.com/view/dr-brahmer-on-the-pd-1-immunotherapy-bms-93655

Dec 20th, 2020 - Julie R. Brahmer, MD, associate professor of oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, discusses a phase I clinical trial that investigated the experimental agent BMS-936558, a targeted immunotherapy agent that...

see more →

Patient Education  3 results see all →